CD8A and neoplasm: For example, a pre-clinical study showed that administering a low dose of the chemotherapy cyclophosphamide (CTX) one day before ACT of tumor-specific CD8 T cells is effective in reducing tumor burden and thereby prevents deletion of the transferred CD8 T cells in a murine lymphoma model (27).